Summit Therapeutics (SMMT) Operating Leases (2018 - 2026)

Summit Therapeutics (SMMT) has 9 years of Operating Leases data on file, last reported at $16.8 million in Q2 2026.

• Quarterly Operating Leases rose 591.33% year-over-year to $16.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $16.8 million (up 591.33% YoY) and the FY2025 annual result came in at $17.5 million, up 406.86% from the prior year.
• Operating Leases held at $16.8 million in Q2 2026, from $16.9 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $17.5 million in Q4 2025 to a low of $1.3 million in Q2 2022.
• A 5-year average of $5.6 million and a median of $3.4 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2025 — Operating Leases tumbled 51.47% — and 2026, when it soared 591.33%.
• Tracing SMMT's Operating Leases over 5 years: stood at $2.8 million in 2022, then advanced by 19.07% to $3.3 million in 2023, then rose by 4.95% to $3.5 million in 2024, then jumped by 406.86% to $17.5 million in 2025, then declined by 3.82% to $16.8 million in 2026.
• The last three Operating Leases figures came in at $16.8 million (Q2 2026), $16.9 million (Q1 2026), and $17.5 million (Q4 2025), per Business Quant data.